A model of impairment and functional limitation in rheumatoid arthritis by Escalante, Agustín et al.
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
BMC Musculoskeletal Disorders
Open Access Research article
A model of impairment and functional limitation in rheumatoid 
arthritis
Agustín Escalante*, Roy W Haas and Inmaculada del Rincón
Address: Division of Rheumatology and Clinical Immunology, Department of Medicine, The University of Texas Health Science Center at San 
Antonio, San Antonio, Texas, USA
Email: Agustín Escalante* - escalante@uthscsa.edu; Roy W Haas - haasr@uthscsa.edu; Inmaculada del Rincón - delrincon@uthscsa.edu
* Corresponding author    
Abstract
Background: We have previously proposed a theoretical model for studying physical disability
and other outcomes in rheumatoid arthritis (RA). The purpose of this paper is to test a model of
impairment and functional limitation in (RA), using empirical data from a sample of RA patients. We
based the model on the disablement process framework.
Methods: We posited two distinct types of impairment in RA: 1) Joint inflammation, measured by
the tender, painful and swollen joint counts; and 2) Joint deformity, measured by the deformed joint
count. We hypothesized direct paths from the two impairments to functional limitation, measured
by the shirt-button speed, grip strength and walking velocity. We used structural equation modeling
to test the hypothetical relationships, using empirical data from a sample of RA patients recruited
from six rheumatology clinics.
Results: The RA sample was comprised of 779 RA patients. In the structural equation model, the
joint inflammation impairment displayed a strong significant path toward the measured variables of
joint pain, tenderness and swelling (standardized regression coefficients 0.758, 0.872 and 0.512, P
≤  0.001 for each). The joint deformity impairment likewise displayed significant paths toward the
measured upper limb, lower limb, and other deformed joint counts (standardized regression
coefficients 0.849, 0.785, 0.308, P ≤  0.001 for each). Both the joint inflammation and joint deformity
impairments displayed strong direct paths toward functional limitation (standardized regression
coefficients of -0.576 and -0.564, respectively, P ≤  0.001 for each), and explained 65% of its variance.
Model fit to data was fair to good, as evidenced by a comparative fit index of 0.975, and the root
mean square error of approximation = 0.058.
Conclusion: This evidence supports the occurrence of two distinct impairments in RA, joint
inflammation and joint deformity, that together, contribute strongly to functional limitations in this
disease. These findings may have implications for investigators aiming to measure outcome in RA.
Background
Physical disability is an important outcome of rheuma-
toid arthritis (RA) [1,2]. The American College of Rheu-
matology preliminary definition of improvement in RA,
used primarily to assess the short term response to medi-
cal interventions, includes disability as one of its seven
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key outcomes [3]. An understanding of disability in RA
requires an appreciation of the interrelationship between
the biology of the disease, the person and his or her psy-
chology, and the social environment [4-7].
Inquiries into physical disability in RA, needing to weigh
the influence of numerous variables interacting over time
in complex ways, benefit from a conceptual framework, or
model [8]. A model informs research by clarifying the
relationships between variables, and facilitates communi-
cation of ideas related to the research in question [9]. In
studying the development of disability in RA, we pro-
posed a theoretical framework [10], which we based on
the disablement process that occurs with aging [8]. Ini-
tially based on purely theoretical grounds, our model pro-
posed strategies to quantify the four sequential stages of
the main disease-disability pathway in RA: pathology →
impairment  →  functional limitation →  physical disability
[10]. A useful device to facilitate the understanding of
these stages of disablement, is to think of them in terms of
the level at which they occur, and can be quantified. Thus,
pathology occurs at the level of molecules, cells, or tissues,
and is measured using tests such as the erythrocyte sedi-
mentation rate, the C-reactive protein concentration,
cytokine expression patterns, or images of the joints
obtained with X-ray or MRI. Impairments are dysfunctions
or structural abnormalities that occur at the level of organs
or organ systems. They include signs and symptoms of
disease such as pain, morning stiffness, joint tenderness,
swelling and deformity. Functional limitations are restric-
tions in basic physical or mental actions, and they involve
the whole person. Although they can be measured in a
number of different ways, we have chosen to use perform-
ance-based functional tests such as the grip strength, walk-
ing velocity and the timed shirt-button test to measure
functional limitations [11]. Disability involves difficulty
with a physical or mental activity, within a social context.
The measurement level therefore should include the per-
son and the societal environment. We have used self
report measures of physical disability such as the Health
Assessment Questionnaire, or the physical function scale
of the SF-36, to measure physical disability [12].
As noted above, we based our initial model and its pro-
posed measurement strategies on purely theoretical
grounds [10]. Since its publication, however, we have pro-
vided initial empirical evidence to support two of the
model's main disease-disability pathway stages, and our
approach to measuring them, using data from a clinical
sample of RA patients. Those two stages are functional lim-
itation and physical disability [11-14]. In the present report,
we show additional data to support our definition of
impairment in RA.
Methods
Patients
From 1996 to 2000, we enrolled consecutive patients
meeting the 1987 RA criteria [15], into a study of the dis-
ablement process in RA We have described our sample in
previous publications [13,14]. Here, we will show cross-
sectional results obtained during the recruitment evalua-
tion of each participant.
Settings
We recruited patients from six outpatient rheumatology
clinics in San Antonio, Texas: 1) An Army Medical Center,
2) An Air Force Medical Center, 3) A private, university-
based clinic, 4) A community-based, seven-rheumatolo-
gist private practice, 5) A county-funded clinic and, 6) A
Veterans Administration clinic. All evaluations were done
on location in these facilities.
Data collection procedures
Our study was approved by the Institutional Review Board
of each of the clinical facilities were we went to recruit
patients, and all patients gave written, informed consent.
A physician or a research nurse, assisted by a trained
research associate, conducted evaluations at the clinic
where the patient was recruited. The evaluation lasted
approximately 90 minutes, and consisted of a compre-
hensive interview, physical examination, review of medi-
cal records, and laboratory and X-ray tests. Interviews were
conducted in either English or Spanish, as preferred by
patients.
Data elements
Impairments
We measured impairments using self-report and physical
examination. We used a validated, one-page joint manne-
quin for patients to mark the joints that were painful or
swollen [16]. This variable is expressed as the painful joint
count. A physician or research nurse, trained in joint
examination techniques, assessed 48 joints in each patient
for the presence or absence of tenderness or pain on
motion, swelling or deformity. Each of these variables is
expressed as a count for the number of affected joints [17].
Functional limitations
We measured functional limitations using the following
performance-based rheumatology function tests: 1. Grip
strength. We measured grip strength with a hand held
JAMAR® Dynamometer (Sammons Preston, Bolingbrook,
Illinois). In a sitting position, with the elbow held at 90
degrees, and the forearm supported on a flat horizontal
surface, patients were asked to squeeze the handle with as
much as strength as possible. Three repetitions from each
hand were recorded, in kilograms. The mean value of all
repetitions for both hands is shown; 2. Walking velocity.
Starting from a standing position, patients were asked toBMC Musculoskeletal Disorders 2005, 6:16 http://www.biomedcentral.com/1471-2474/6/16
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walk at their usual pace, for a distance of 50 feet, or 25 feet
if they had difficulty covering the full distance. No effort
was made to conceal the stopwatch used to time the
patients. Results are expressed in feet per second. Patients
unable to walk were assigned a velocity of 0 feet per
minute; 3. Timed button test. Patients were asked to don
and fasten the front buttons of a standard eight-button,
men or women's extra-large, denim shirt (Wal-Mart, San
Antonio, Texas). A stop watch was activated when the
patient took the shirt as it was offered by the examiner,
and stopped when the last button was fastened. This test
quantifies the performance and large and small upper
extremity joints. Results are expressed as buttons per
minute. Patient unable to don the shirt were assigned a
value of 0 buttons per minute.
Analysis
We began the analysis by inspecting summary statistics
and histograms of all study variables. Skewed variables
were square root transformed toward normality. We spec-
ified a structural equation model (SEM) of impairment
and functional limitation in RA [18]. We hypothesized
that impairment in RA is represented by two distinct con-
structs. The first of these is characterized by joint inflam-
mation & pain, the second by joint deformity. Each of
these two constructs is represented by a latent variable in
the model. The inflammation-pain construct is measured
by a physical examination joint count for tenderness and
swelling [17], and a self-reported joint count of painful
joints [16]. The joint deformity construct is measured by
the deformed joint count [17]. Because a latent variable is
more reliably measured by two or more measures, we dis-
aggregated the deformed joint count into upper and lower
extremities counts, and a count for other joints. The latter
included the temporo-mandibular, acromio-clavicular
and sterno-clavicular joints. We assessed the influence of
joint impairment on functional limitation, the next stage
in the RA disablement process, by positing a direct path
from the former to the later in the SEM. As we have shown
previously [11], we defined functional limitation as a
latent variable measured by three rheumatology function
tests: grip strength, shirt-button speed and walking veloc-
ity over 50 feet [11]. We used a maximum likelihood pro-
cedure to estimate the model parameters. Once these were
estimated, we examined modification indices seeking
parameters not estimated in the initial model, that may
increase model fit if added to the model. Here, it is impor-
tant to keep in mind that structural equation modeling is
not meant to be a data-driven technique, rather, it should
be a theory-driven one [18]. We therefore only considered
parameters that would not substantially change the basic
structure of the model, i.e. one with two impairment
latent variables and one functional limitation latent vari-
able. Also after specifying the initial model, we evaluated
a the effect of adding a direct path from the joint inflam-
mation to the joint deformity latent variables. We quanti-
fied the degree of fit of the hypothetical model to our
empirical data using the comparative fit index (CFI), the
normed fit index (NFI), and the root mean square error of
approximation (RMSEA). Interpretation of these fit indi-
ces is subjective, and there are no universally accepted
guidelines. Generally, fit index values ≥  0.95 are consid-
ered to indicate acceptable fit of a model to data [18].
RMSEA values ≤  0.05 indicate close fit, values ≤  0.08 indi-
cate reasonable error of approximation [19]. We used the
parameter estimates for the latent variables to compute
their values and plot frequency distributions for each one.
We used the Amos 5.0 statistical pathway package to spec-
ify and test the SEM. (SmallWaters Corporation, Chicago,
Illinois).
Results
We recruited 779 patients from 1996 to 2000. We have
described the clinical characteristics of the study sample in
earlier publications [13,14]. Briefly, from 1996 to 2000,
we recruited consecutive patients who met the 1987 crite-
ria for the classification of RA [15], from six rheumatology
clinics in San Antonio, Texas. In addition to having RA,
patients had to be 18 years of age or older. No other inclu-
sion or exclusion criteria were applied. The median age of
the patients was 57 years (min to max 19 to 90), 70% were
women and 56% were Hispanic. The median number of
years of formal education was 12 (min to max 0 to > 16),
21% were working full- or part-time, 27% were disabled
from work. The median disease duration was 8 years (min
to max 0 to 52). Mean joint counts were 15 for tender, 7
for swollen and 10 for deformed. Subcutaneous nodules
were present in 30%, and rheumatoid factor in 89%. The
joint counts displayed skewed distributions. Square root
transformation reduced skewness from tender, swollen
and painful joint counts, but not from the deformed joint
counts. We used the transformed values for the former
three variables, but used the unstransformed deformed
joint count in the SEM.
A graphical display of the proposed model is shown in
Figure 1. We hypothesize that two distinct impairments
take place in RA, each represented by a latent variable in
the SEM. The two impairments, joint inflammation and
joint deformity, are shown as ovals on the left side of Fig-
ure 1. Joint inflammation is measured by the extent of
joint tenderness, joint swelling and joint pain, shown in
boxes in Figure 1. Table 1 lists the path coefficients from
joint inflammation to the measured variables. All three
were large, and statistically significant. The standardized
coefficient was > 0.5 for each measured variable, suggest-
ing the a standard deviation change in the latent variable
of joint inflammation, is associated with a change in the
measured variables of at least one half standard deviation
(Table 1).BMC Musculoskeletal Disorders 2005, 6:16 http://www.biomedcentral.com/1471-2474/6/16
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The latent variable of joint deformity is measured by the
deformed joint count, which we disaggregated into counts
for the joints in the upper and lower extremities, and
other joints. The path coefficients for upper and lower
extremity deformities were stronger than that of the other
joints (i.e. temporo-mandibular, acromio-clavicular and
sterno-clavicular joints), but all three remained significant
Table 1).
To obtain a better understanding of the properties of the
latent variables, we used the path coefficients from the
two impairment latent variables to compute their esti-
mated values, generating a new variable for each one. Fig-
ures 2 and 3 show the distribution of the two impairment
latent variables, after rescaling them variables to vary from
0 to 100. Joint inflammation displayed a characteristic
Gaussian distribution (Figure 2). This was not the case for
joint deformity, however, which remained skewed by the
a substantial number of patients who lacked deformities
on physical examination (Figure 3).
In the structural equation model, both of the impairment
latent variables displayed strong direct paths toward func-
tional limitations. The standardized coefficients were -0.5
Identification diagram of a structural equation model of the relationship between the stages of impairment and functional limi- tation in rheumatoid arthritis Figure 1
Identification diagram of a structural equation model of the relationship between the stages of impairment and functional limi-
tation in rheumatoid arthritis. Two types of impairment, joint inflammation and joint deformity are shown as ovals on the left. 
Measurements for these latent variables include joint tenderness (JT), joint swelling (JS) and joint pain (JP), for joint inflamma-
tion; and joint deformities. We disaggregated joint deformities into upper limb (DUL), lower limb (DLL) joints, and other joints 
(DOJ). Several of the parameters were constrained to enable estimation. Circles represent residuals or disturbance terms, for 
each variable. See Table 1 for parameter estimates.BMC Musculoskeletal Disorders 2005, 6:16 http://www.biomedcentral.com/1471-2474/6/16
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or less, representing a change of more than half a standard
deviation in the functional limitations for every standard
deviation change in the impairments (Table 1). The
squared multiple correlation of functional limitation was
0.65, suggesting that impairments explain 65% of func-
tional limitation's variance.
Table 1: Parameter estimates from a structural equation model of joint impairment on functional limitations in RA.
Parameter estimates
Direct Paths Unstandardized SE P-value Standardized
Joint inflammation → Functional limitation -.377 0.029 ≤  0.001 -0.576
Joint deformity → Functional limitation -0.088 0.007 ≤  0.001 -0.564
Joint tenderness → Joint inflammation 1.000 0.872
Joint pain → Joint inflammation 0.837 0.046 ≤  0.001 0.758
Joint swelling → Joint inflammation 0.445 0.034 ≤  0.001 0.513
Upper limb joint deformity → Joint deformity 1.000 0.849
Lower limb joint deformity → Joint deformity 0.478 0.029 ≤  0.001 0.785
Other joint deformity → Joint deformity 0.011 0.001 ≤  0.001 0.308
Functional limitation → Grip strength 1.000 0.773
Functional limitation → Walking velocity 0.958 0.051 ≤  0.001 0.740
Functional limitation → Button speed 0.046 0.002 ≤  0.001 0.757
Correlations*
Upper extremity deformity ←→ Other joint deformity -0.22 --- 0.004 ---
Walking velocity ←→ Shirt button speed 0.274 --- ≤  0.001 ---
Parameters estimated using maximum likelihood with Amos 4.0. See Figure 1 for a diagram of the specification model.
* Correlation shown are between the residuals of the measured variables.
Frequency distributions of the joint inflammation (JI) impair- ment latent variable Figure 2
Frequency distributions of the joint inflammation (JI) impair-
ment latent variable. This was computed from JI = JT1/2 + JS1/2 
× 0.445 + JP1/2 × 0.837, where JT = joint tenderness, JS = joint 
swelling, and JP = joint pain. Weights were estimated using 
maximum likelihood with Amos, after constraining the coeffi-
cients for JT and DUL to 1. The latent variable was then 
rescaled to vary from 0 to 100.
Frequency distributions of the joint deformity (JD) impair- ment latent variable Figure 3
Frequency distributions of the joint deformity (JD) impair-
ment latent variable. This was computed from JD = DUL + 
DLL × 0.478 + DOJ × 0.011, where DUL = deformity upper 
limb, DLL = deformity lower limb, and DOJ = deformity 
other joints. The weights for the equation were estimated 
using maximum likelihood with Amos, after constraining the 
coefficients for JT and DUL to 1. The latent variable was then 
rescaled to vary from 0 to 100.BMC Musculoskeletal Disorders 2005, 6:16 http://www.biomedcentral.com/1471-2474/6/16
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The initial CFI and NFI of the model were both 0.95, sug-
gesting a close fit of the model to the data. The initial
RMSEA was 0.07, suggesting reasonable fit [19]. Modifica-
tion indices suggested a number of potential parameters
that could increase model fit if added to the estimation
model. Most of these did not make clinical sense, or ran
counter to the a priori model we were testing, and we
therefore did not specify them. However, we noted two
covariances that would increase model fit without altering
the overall structure of the model. The first of these was
between the residuals of the measured variables for
deformities in the upper extremity and deformities in
other joints; the second, between residuals for walking
velocity and the timed button test. After specifying these
two covariances, CFI increased to 0.975, NFI to 0.966, and
RMSEA decreased to 0.058. Also post hoc, we tested a direct
path between joint inflammation and joint deformity, but
the resulting coefficient was small and did not reach sta-
tistical significance. We therefore omitted an inflamma-
tion →  deformity path from the final model.
Discussion
Several models have been proposed to study disability in
the general population [8,9,20], and can be applied to
study RA and other types or arthritis [10,21,22]. The
World Health Organization (WHO) has developed the
International Classification of Functioning, Disability and
Health (ICF), with a corresponding set of core measures
for a number of chronic conditions [21]. One set of ICF
core measures has been proposed for RA [21]. It includes
a comprehensive range of body structures and functions,
activities and participation that can be assessed in studies
of disability in RA [21]. The ICF classifies its components
into categories that are analogous to the disablement
process stages: body structures and functions in the ICF are
analogous to the stages of pathology and impairment,
while activities and participation correspond to functional
limitations and disability in the disablement process [22].
We chose the disablement process over other disability
models, among other reasons, because it considers the
stages in disablement as an explicit sequence of linked
events, one leading to the next. Rather than suggesting
specific functions or activities to measure, it offers broad
definitions of each stage, leaving it up to investigators to
find ways to test them. Several of the variables we include
in the present analysis are represented in the ICF classifi-
cation, including joint pain and deformity, and walking.
Variables not represented in the ICF, but which we did
obtain, include joint tenderness and swelling, and grip
strength. Our measurement of the stage of disability,
described elsewhere, has considerable homology with
that of the ICF [12]. The most important difference
between our RA disablement model and the ICF classifica-
tion, is that the latter does not contemplate the stage of
pathology with sufficient detail for our aim, to map path-
ways from disease to disability in RA.
We used the disablement process framework to build a
model of impairment and functional limitation in RA [8].
Impairments occur when pathology at the level of the
molecule, cell or tissue, crosses the clinical horizon caus-
ing symptoms or signs of disease. They represent derange-
ment of structure or function at the organ level.
Consistent with this framework, we used the articular
manifestations of RA, joint pain, tenderness, swelling and
deformity, to measure impairment. It should be noted
that we consider impairment to be theoretical construct
that cannot be directly quantified. We studied it as a latent
variable, the articular signs and symptoms listed above
serving as the tools we used to tap into the impairment
construct.
The concept of impairment as a stage in the disablement
process is not intended to oversimplify the anatomical or
physiological derangements that occur within that stage.
In fact, the derangements can be quite complex,
depending on the nature of the initial pathology, and the
organ system under study. In the case of rheumatoid
joints, the initial pathology can be broadly classified into
two discrete, but related groups: inflammation and dam-
age [10]. It should be noted that we did not include meas-
ures of these two pathological processes here. However,
because impairments are tied to their underlying pathol-
ogy, we posited two types of impairments, one for each
type of joint pathology. The first type is related to inflam-
mation in the joints, and the other to damage. The former,
we measured using tender, swollen and painful joint
counts, the latter, using the deformed joint count.
Both impairment latent variables displayed strong, statis-
tically significant path coefficients toward the measured
variables, providing evidence that the measures we chose
adequately tap into the proposed impairments. In the
diagram of our model, these paths are shown as arrows
from the latent to the measured variables, to indicate that
it is the joint inflammation or damage (both of them
latent variables), that are "causing" the joint signs and
symptoms that we are able to measure. Not included in
our final model because it did not reach statistical
significance, was a path from joint inflammation to
deformity. This is likely because we restricted the present
analysis to the stages of impairment and functional limi-
tation. Although there is considerable evidence that
inflammation leads to damage in RA joints, the link
between the two processes occurs during the stage of
pathology, not impairment. We expect to find a strong
link between inflammation and damage when we extend
our analyses to include pathology measures such as theBMC Musculoskeletal Disorders 2005, 6:16 http://www.biomedcentral.com/1471-2474/6/16
Page 7 of 8
(page number not for citation purposes)
erythrocyte sedimentation rate, C-reactive protein, joint
erosions and joint space narrowing.
According to disablement theory, impairments lead to
functional limitations [8,10]. We expected that this
should translate into a link between variables represent-
ing these two stages. We thus posited direct paths from
each type of impairment to a latent variable representing
functional limitations. We have shown previously that
functional limitations can also be represented as a latent
variable [12], and that it can be measured satisfactorily
using the performance-based rheumatology function
tests, grip strength, walking velocity and the shirt-button
test [12]. We found strong path coefficients from both
impairment latent variables to the functional limitation
latent variable (Figure 1). Moreover, the impairments
accounted for 65% of the variance in functional limita-
tions. Both these findings provide additional support for
our definition of rheumatoid impairments and functional
limitations.
The disablement process was proposed as a framework to
aid investigators in their efforts to understand the devel-
opment of disability in aging, and in specific disease states
[8]. The framework's acknowledgement of the sequential
nature of a disease's manifestations make it especially
informative to inquiries into disability in chronic dis-
eases. It is worthy of attention that the disablement model
can also be applied advantageously to outcomes other
than disability.
One of our goals with this and earlier efforts to model
RA's stages [10-12], is to improve the current interpreta-
tion of the disease's outcome. Current systems used to
assess RA's outcome mix stages of the disease process,
without regard to their sequential nature, or omit some
stages altogether [3,23]. For example, the improvement
criteria of American College of Rheumatology (ACR),
define response on the basis of the ACR's core set of RA
disease activity measures [24]. These measures, although
empirically tested in clinical trials, were adopted without
reference to an explicit model of the disease. The improve-
ment criteria include measures of pathology (i.e. the
erythrocyte sedimentation rate or the C-reactive protein),
impairment (i.e. the tender and swollen joint counts, glo-
bal assessment of disease activity, pain scale), and disabil-
ity (i.e. the Health Assessment Questionnaire). They do
not include measures of functional limitation [3].
The success with which the ACR and similar response
measurement systems have been used in clinical trials,
does not preclude the possibility that they could be
improved [25]. Mixing or omitting disease stages may
dilute a response measurement system's ability to detect
the effect of treatments targeted at the early stages of the
disease process. Although treatments that are primarily
anti-inflammatory may indeed affect late disease stages
such as physical disability, their effect is indirect, medi-
ated through their primary effect on the inflammatory
process. We have proposed what we believe would be a
more rational approach to outcome assessment, using the
stages of the disablement model to inform the selection of
outcome measures [10]. Thus, measures of pathology and
impairment would best capture response to anti-inflam-
matory therapies, while measures of functional limitation
would best capture response to joint surgery or other reha-
bilitation interventions [10]. Empirical data to test our
proposal would be of great interest.
Certain constraints apply to the interpretation of our find-
ings. The maximum likelihood estimator that we used for
SEM assumes multivariate normality, a requirement that
is not strictly met by some of the variables we used in this
analysis. Non-normality may affect standard errors, and
thus significance testing, about the parameter estimates,
albeit not the value of the parameters themselves. The
overall structure of the model we propose, i.e. two distinct
impairments linked to functional limitations, is thus
likely to be unaffected by this deviation from assump-
tions. The patient sample we studied is sufficiently large
that the potential deleterious effect of non-normality on
the significance of the path coefficients may be offset. It
should also be noted that data we used here to test the
impairment  →  functional limitation relationship are
cross-sectional. The sequential link between the two
stages we propose has face validity in that joint tender-
ness, swelling and deformity are causes, not conse-
quences, of diminished grip strength, walking velocity
and shirt button speed. Nevertheless, confirmation of our
findings in a longitudinal dataset would strengthen the
evidence for the model.
Conclusion
We conclude that two distinct impairments occur in RA,
one characterized by signs and symptoms of joint
inflammation, the other by joint deformity. Both of these
contribute substantially to the functional limitations that
occur in this disease.
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Table 2: Squared multiple correlations of impairments and 
functional limitations
VARIABLE R2
Joint Deformity‡ 0.000
Joint Inflammation‡ 0.000
Functional Limitation‡ 0.650
Upper limb joint deformities 0.617
Lower Limb Joint Deformities 0.722
Other joint Deformities 0.095
Shirt-button time 0.574
Walking velocity 0.547
Grip strength1/2 0.598
Tender joint count1/2 0.761
Swollen Joint Count1/2 0.263
Painful Joint Count1/2 0.574
Posited relationships between variables are shown graphically in 
Figure 1.
‡ Identifies latent variables